Matulay J - Search Results

1

Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage.

Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Brooks N, et al. Among authors: matulay j. Eur Urol Oncol. 2021 Oct;4(5):826-828. doi: 10.1016/j.euo.2020.03.004. Epub 2020 May 29. Eur Urol Oncol. 2021. PMID: 32475716

2

Long-term Survival Outcomes With Intravesical Nanoparticle Albumin-bound Paclitaxel for Recurrent Non-muscle-invasive Bladder Cancer After Previous Bacillus Calmette-Guérin Therapy.

Robins DJ, Sui W, Matulay JT, Ghandour R, Anderson CB, DeCastro GJ, McKiernan JM. Robins DJ, et al. Among authors: matulay jt. Urology. 2017 May;103:149-153. doi: 10.1016/j.urology.2017.01.018. Epub 2017 Feb 2. Urology. 2017. PMID: 28163086 Clinical Trial.

3

Editorial Comment.

Matulay JT, Anderson CB. Matulay JT, et al. J Urol. 2017 Sep;198(3):573. doi: 10.1016/j.juro.2017.02.3377. Epub 2017 May 29. J Urol. 2017. PMID: 28571938 No abstract available.

4

Conservative Management Following Complete Clinical Response to Neoadjuvant Chemotherapy of Muscle Invasive Bladder Cancer: Contemporary Outcomes of a Multi-Institutional Cohort Study.

Mazza P, Moran GW, Li G, Robins DJ, Matulay JT, Herr HW, Decastro GJ, McKiernan JM, Anderson CB. Mazza P, et al. Among authors: matulay jt. J Urol. 2018 Nov;200(5):1005-1013. doi: 10.1016/j.juro.2018.05.078. Epub 2018 May 19. J Urol. 2018. PMID: 29787740 Free PMC article.

5

Advances in risk stratification of bladder cancer to guide personalized medicine.

Matulay JT, Kamat AM. Matulay JT, et al. F1000Res. 2018 Jul 25;7:F1000 Faculty Rev-1137. doi: 10.12688/f1000research.14903.1. eCollection 2018. F1000Res. 2018. PMID: 30109022 Free PMC article. Review.

6

The impact of squamous histology on survival in patients with muscle-invasive bladder cancer.

Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. Matulay JT, et al. Urol Oncol. 2019 Jun;37(6):353.e17-353.e24. doi: 10.1016/j.urolonc.2019.01.020. Epub 2019 Jan 28. Urol Oncol. 2019. PMID: 30704959

7

Clinical and Genomic Considerations for Variant Histology in Bladder Cancer.

Matulay JT, Narayan VM, Kamat AM. Matulay JT, et al. Curr Oncol Rep. 2019 Feb 26;21(3):23. doi: 10.1007/s11912-019-0772-8. Curr Oncol Rep. 2019. PMID: 30806832 Review.

8

A Case for Risk-adapted Management of Low-grade Bladder Tumors.

Soloway M, Matulay JT, Kamat AM. Soloway M, et al. Eur Urol Oncol. 2020 Feb;3(1):128-129. doi: 10.1016/j.euo.2019.09.007. Epub 2019 Oct 20. Eur Urol Oncol. 2020. PMID: 31645295

9

Risk-adapted management of low-grade bladder tumours: recommendations from the International Bladder Cancer Group (IBCG).

Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Palou J, Colombel M, Brausi M, Kamat AM. Matulay JT, et al. BJU Int. 2020 Apr;125(4):497-505. doi: 10.1111/bju.14995. Epub 2020 Feb 8. BJU Int. 2020. PMID: 31950596 Review.

10

Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes.

Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Narayan VM, et al. Urol Oncol. 2020 Apr;38(4):247-254. doi: 10.1016/j.urolonc.2019.12.005. Epub 2020 Jan 14. Urol Oncol. 2020. PMID: 31953001

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters